NPT520 34
Alternative Names: NPT 520-34Latest Information Update: 28 Jun 2023
At a glance
- Originator Neuropore Therapies
- Class Anti-inflammatories; Antidementias; Antiparkinsonians; Neuroprotectants; Neuropsychotherapeutics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase modulators; Autophagy stimulants; Organic anion transport protein 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Neurodegenerative disorders; Parkinson's disease
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO, Capsule)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA (PO, Capsule)
- 28 Jun 2022 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis(In volunteers) in USA (PO, Capsule)